Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis

Trial Profile

Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms AbsorbISR
  • Most Recent Events

    • 27 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 27 Apr 2017 Status changed from recruiting to discontinued as according to ClinicalTrials.gov; information of other studies with Abseb bioresorbable scaffolds showed a higher thrombotic risk than before, the risk for the patients is estimated too high.
    • 20 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top